Search results
Ready to Sell Moderna? Check Out This Chart First
Motley Fool· 2 years agoModerna (NASDAQ: MRNA) was a winning investment during the early days of the pandemic. The coronavirus vaccine leader climbed more than 400% in 2020....
The Covid Gambit: Pfizer, Moderna Struggle To Get The Jump On Covid
Investor's Business Daily· 2 years agoPfizer, BioNTech and Moderna are working feverishly to launch new Covid boosters ahead of a fall...
What the CDC's New COVID-19 Vaccine Recommendations Mean for You
Time via Yahoo News· 1 year agoSyringes containing the Moderna COVID-19 vaccination for children 6 months to 5 years old, at Temple...
FDA panel unanimously endorses Pfizer and Moderna COVID-19 shots for babies and little kids
Business Insider via Yahoo News· 2 years agoDr. Barry Diener and Ilana Diener hold their three-year-old son, Hudson, during an appointment for a...
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoInvestors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates...
Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?
Motley Fool· 2 years agoCOVID-19 hasn't gone away. But a quick look at the charts of Pfizer (NYSE: PFE) and Moderna (NASDAQ:...
Moderna May Be Just Getting Started in This Big Market
Motley Fool· 1 year agoModerna is ready to tackle this market this year -- and revenue should climb once it does. In fact,...
1 Picture That Sums Up Moderna's Biggest Problem
Motley Fool· 2 years agoYou might think that investors would love Moderna (NASDAQ: MRNA) based on its business performance. It's on track to sell $21 billion of its COVID-19...
Novavax's (NVAX) COVID Jab Gets Full Approval in Europe
Zacks via Yahoo Finance· 11 months agoNovavax NVAX announced that the European Commission had granted full marketing authorization for its...
The Chef's Warehouse and AZEK have been highlighted as Zacks Bull and Bear of the Day
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – June 30, 2022 – Zacks Equity Research shares The Chef's...